Exhibit 23.1


          Consent of Independent Registered Public Accounting Firm
          --------------------------------------------------------

The Board of Directors and Shareholders
K-V Pharmaceutical Company:

We consent to the incorporation by reference in the registration statements
(Nos. 33-46400, 33-44927, 333-48252 and 333-85516) on Form S-8 and
registration statements (Nos. 333-87402 and 333-106294) on Form S-3 of our
reports dated June 14, 2005, with respect to the consolidated balance sheet
of K-V Pharmaceutical Company and subsidiaries as of March 31, 2005, the
related consolidated statements of income, comprehensive income,
shareholders' equity and cash flows for the year ended March 31, 2005, and
the related financial statement schedule for the year ended March 31, 2005,
management's assessment of the effectiveness of internal control over
financial reporting as of March 31, 2005, and the effectiveness of internal
control over financial reporting as of March 31, 2005, which reports appear
in the March 31, 2005 annual report on Form 10-K of K-V Pharmaceutical
Company.

As discussed in Note 2 to the consolidated financial statements, during
fiscal 2005, the Company adopted the provisions of Emerging Issues Task
Force (EITF) Issue No. 03-6 Participating Securities and the Two-Class
Method under FASB Statement No. 128 and EITF Issue No. 04-8 The Effect of
Contingently Convertible Instruments on Diluted Earnings per Share.


/s/ KPMG LLP


St. Louis, Missouri
June 14, 2005